全球抗凝剂市场 – 行业趋势及 2030 年预测

 抗凝剂市场分析及规模

根据美国疾病控制与预防中心的数据，男性和女性患血管性血友病 (VWD) 的几率相同，这种疾病影响了高达 1% 的普通人群。2012 年至 2016 年期间，超过 14,600 名男性、女性和儿童在血友病治疗中心接受了血管性血友病 (VWD) 治疗；其中约三分之二是女性和女孩。因此，预计在预测期内，凝血障碍病例的增加将推动全球市场的发展。

Data Bridge Market Research 分析，抗凝剂市场在 2022 年的规模为 6090 万美元，预计到 2030 年将达到 9417 万美元，在 2023 年至 2030 年的预测期内的复合年增长率为 5.6%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

抗凝剂市场范围和细分  

Market Definition

Anticoagulants are medications that aid in the prevention of blood clots. They are given to people at high risk of clotting to lower their chances of developing serious conditions such as strokes and heart attacks. A blood clot is a seal formed by blood to stop bleeding from wounds. If a blood clot prevents blood from flowing through a vessel, the affected area of the body will be deprived of oxygen and may cease to function properly. Aspirin, heparin, and warfarin are examples of anticoagulants.

Anticoagulant Market Dynamics

Drivers

• Increase in Elderly Population

People over the age of 65 are the world's fastest growing demographic segment, according to the World Health Organization (WHO). The proportion of the world's population over the age of 60 is expected to double between 2000 and 2050, rising from about 11% to 22%. According to the CDC, approximately 2% of people under the age of 65 have atrial fibrillation, while 9% of people over the age of 65 have the disease. It is also predicted that by 2030, nearly 12.1 million people will have atrial fibrillation. As a result, during the forecast period, the growing elderly population will drive the global anticoagulant reversal drugs market growth.

• Increase in Hip and Knee Surgeries 

The rising number of knee and hip replacement surgeries increases the likelihood of developing deep vein thrombosis (DVT). Surgery frequently results in prolonged immobility, which increases the risk of DVT due to decreased blood flow in the body. The number of surgical procedures performed on the elderly population has increased, according to the WHO 2016 report. The increased number of surgeries is expected to increase the likelihood of thromboembolic events following surgery, increasing patient demand for anticoagulant treatment.

Opportunities

• Rising Use of Warfarin

Some medications, such as blood thinners such as warfarin, heparin, and aspirin, can cause bleeding disorders. The anticoagulant agent used influences the high risk of bleeding. According to the National Center for Biotechnology Information (NCBI), bleeding in warfarin patients is estimated to be 15-20% each year. Warfarin-related life-threatening bleeding is expected to occur at a rate of 1-3% per year. As a result of the increased demand for anticoagulant therapies, potential opportunities for anticoagulant reversal agents are emerging.

Restraints/Challenges

• Side Effects of Medicines

Some medications can have a negative impact on the health of the population, particularly the elderly. It can sometimes cause excessive bleeding, and the higher dosage can cause a slew of complications. As a result, drug side effects limit the growth of the global anticoagulant reversal drugs market.

This anticoagulant market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anticoagulant market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2019, Bristol-Myers Squibb-Pfizer Alliance received safety and efficacy data for Eliquis for the treatment of venous thromboembolism in cancer patients. This efficacy data aided the company in providing physicians and patients with more opportunities to treat venous thromboembolism, resulting in increased product sales.
• In 2019, Cipla Inc. signed a partnership agreement with Wellthy Therapeutics Private Limited to provide digital therapeutics to cardiovascular disease patients. Because the company provides anticoagulants for the treatment of cardiovascular disease, this collaboration assisted the company in improving its platform for anticoagulant drugs by providing all anticoagulant therapy-related information through a digital platform.

Global Anticoagulant Market Scope

The anticoagulant market is segmented on the basis of drug class, therapeutic areas, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Vitamin K Antagonist (Warfarin)
• Non-VKA Oral Anticoagulants (NOACS)
• Eliquis
• Bevyxxa
• Xarelto
• Savaysa and lixiana
• pradaxa
• Heparin and LMWH
• Thrombin Inhibitors (Dabigatran)

 Therapeutic Areas

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Atrial Fibrillation
• Heart Attack, Stroke
• Unstable Angina
• Hip or Knee Replacement Surgery
• Others

 Route of Administration

• Oral
• Parenteral

 End User

• Hospitals
• Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Others

 Distribution Channel

• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Anticoagulant Market Regional Analysis/Insights

The anticoagulant market is analyzed and market size insights and trends are provided by country, drug class, therapeutic areas, route of administration, end user and distribution channel as referenced above.

抗凝剂市场报告涵盖的国家包括南美洲的巴西、阿根廷和南美洲其他地区。

北美凭借其完善的医疗保健基础设施和优惠的报销政策在抗凝剂市场占据主导地位。

由于膀胱癌、食道癌、肝癌、胰腺癌等癌症的发病率不断增加，以及美国各大制造商的广泛存在，此外，技术进步和外国投资不断增加，预计亚太地区将在 2023 年至 2030 年的预测期内以最高的增长率增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

抗凝剂市场还为您提供每个国家/地区资本设备医疗保健支出增长、抗凝剂市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对抗凝剂市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

竞争格局和抗凝剂市场份额分析

抗凝血剂市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对抗凝血剂市场的关注有关。

抗凝剂市场的一些主要参与者包括：

• 辉瑞公司 (美国)
• 阿斯利康（英国）
• 百时美施贵宝公司 (美国)
• Dr. Reddy's Laboratories Ltd（印度）
• Endo International plc（爱尔兰）
• 梯瓦制药工业有限公司 (以色列)
• 太阳制药工业有限公司 (印度)
• Mylan NV（美国）
• 诺华公司（瑞士）
• 鲁冰花（印度）
• Cipla Inc（印度）
• Aurobindo Pharma（印度）
• 赛诺菲（法国）
• 默克公司（美国）
• Amneal Pharmaceuticals LLC.（英国）
• Alvogen（美国）
• Bausch Health Companies Inc.（加拿大）

SKU-53254